Perrigo labeling deferrals
This article was originally published in The Tan Sheet
Executive Summary
FDA grants private labeler's request for varying deferral dates from OTC labeling final rule, depending on when agency labeling templates become available (1"The Tan Sheet" Oct. 1, p. 3). In Dec. 11 letter, FDA concludes that based on amount of time it has taken to finalize labeling templates for several ANDA drug products, "we consider your timetable for concurrent implementation of labeling revisions for [these] products to be appropriate." Implementation deferrals apply to clemastine fumarate tablets, doxylamine succinate tablets, pseudoephedrine HCl extended release and minoxidil topical solution, all of which did not have finalized FDA labeling templates as of Oct. 1...
You may also be interested in...
FDA "Drug Facts" Templates Supersede Reference Listed Drug Labeling - FDA
Generic drugs approved under ANDAs may conform to "Drug Facts" labeling as it appears in templates posted on FDA's Web site without having to wait for the reference listed drug's labeling to be approved.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.